Market Currents
AstraZeneca's (AZN -1.8%) purchase of Ardea Biosciences (RDEA +51.5%) may be the first in a...
-
Monday, April 23, 2012, 12:22 PM ETAstraZeneca's (AZN -1.8%) purchase of Ardea Biosciences (RDEA +51.5%) may be the first in a series of deals for the company. The drug developer is considering buying other late-stage assets outside its research and development focus on cancer, diabetes and gastrointestinal ailments, in an effort to counter looming generic competition.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
